Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Paratek Pharmaceuticals Inc banner
P

Paratek Pharmaceuticals Inc
F:N4CN

Watchlist Manager
Paratek Pharmaceuticals Inc
F:N4CN
Watchlist
Price: 2.024 EUR Market Closed
Market Cap: €115.9m
Write Note Create Alert Ask AI

Paratek Pharmaceuticals Inc
Investor Relations

Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. The company is headquartered in Boston, Massachusetts and currently employs 207 full-time employees. The company went IPO on 2006-05-10. The firm is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use. The firm's lead product, NUZYRA (omadacycline), is an oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia (CABP), and acute skin and skin structure infections (ABSSSI), caused by susceptible pathogens. Omadacycline is used in the emergency room, hospital, and community care settings. Its second product, SEYSARA (Sarecycline), is an oral therapy for the treatment of moderate to severe acne vulgaris.

Show more
Loading
N4CN
DAX Index
1Y 3Y 5Y 10Y 15Y 20Y
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q1 2023
Call Date
May 9, 2023
Q1 2023 Earnings Call
No Analysis Available

This earnings call has not been analyzed yet.

If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.

Request Earnings Call Analysis
Earnings Call Recording
Open Transcript
Other Earnings Calls
2023
Q1

Management

Mr. Michael F. Bigham CPA, CPA, M.B.A., MBA
Exec. Chairman
No Bio Available
Dr. Evan Loh FACC, FAHA, M.D.
CEO & Director
No Bio Available
Mr. Adam Woodrow
Pres & Chief Commercial Officer
No Bio Available
Ms. Sarah Higgins
VP of Fin., Controller & Principal Accounting Officer
No Bio Available
Mr. Jason Burdette
Sr. VP of Technical Operations
No Bio Available
Mr. Ben Strain
VP of Investor Relations & Corp. Communications and Chief of Staff to the CEO
No Bio Available
Mr. William M. Haskel
Sr. VP, Chief Legal Officer, Gen. Counsel, Corp. Sec. & Chief Compliance Officer
No Bio Available
Ms. Karen McGrath
Sr. VP of HR
No Bio Available
Mr. Randall B. Brenner
Chief Devel. & Regulatory Officer
No Bio Available

Contacts

Address
MASSACHUSETTS
Boston
75 Park Plz Ste 4
Contacts
+16178076600.0
paratekpharma.com
sparklesyt

See Also

Summary
N4CN intrinsic value, competitors valuation, and company profile.
DCF Valuation
N4CN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
N4CN stock valuation using valuation multiples.
Wall Street Estimates
N4CN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
N4CN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Back to Top
ALPHA SPREAD
Follow us
Join more than 315,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.